The ARRIBA concept: Adequate resorption of ribavirin

Antiviral Therapy

Volumn 20, Issue 5, 2015, Pages 515-520

  De Kanter, Clara T M M ^a   Koning, Ludi ^b   Berden, Floor A C ^a   Wasmuth, Jan Christian ^c   Grintjes Huisman, Karin J T ^a   Becker, Brigitta ^c   Colbers, Angela P H ^a   Roukens, Monique M B ^a   Rockstroh, Jürgen K ^c   Drenth, Joost P H ^a   De Knegt, Robert J ^b   Dofferhoff, Anton S M ^d   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS C; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SUSTAINED VIROLOGICAL RESPONSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MIXED INFECTION; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; COINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84947224895     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2935     Document Type: Article

References (31)

1. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
3. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369:678-679.
4. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
5. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
6. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
7. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a Phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384:403-413.
8. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, doubleblind, placebo-controlled Phase 3 trial. Lancet 2014; 384:414-426.
9. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22:555-565.
10. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferonalpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55:360-367.
11. Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47:124-129.
12. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
13. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48:138-144.
14. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13:607-611.
15. Breilh D, Foucher J, Castera L, et al. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:487-494.
16. van Vlerken LG, de Kanter CT, Boland GJ, et al. Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome. Ther Drug Monit 2013; 35:546-551.
17. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62:1174-1180.
18. Brochot E, Castelain S, Duverlie G, et al. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther 2010; 15:687-695.
19. Loustaud-Ratti V, Carrier P, Rousseau A, et al. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig Liver Dis 2011; 43:850-855.
20. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47:1453-1461.
21. Loregian A, Scarpa MC, Pagni S, Parisi SG, Palu G. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:358-364.
22. D'Avolio A, Ibanez A, Sciandra M, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 835:127-130.
23. Conti F, Vukotic R, Lorenzini S, et al. Increase of ribavirin dose improves sustained virological response in HCVgenotype 1 patients with a partial response to peg-interferon and ribavirin. Ann Hepatol 2014; 13:196-203.
24. Piedoux S, Monnet E, Piroth L, et al. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C. Antivir Ther 2011; 16:1317-1326.
25. Labarga P, Barreiro P, da Silva A, et al. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis 2012; 206:961-968.
26. Fernández-Rodríguez CM, Morillas RM, Masnou H, et al. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. Gastroenterol Hepatol 2014; 37:1-8.
27. Mangia A, Dalgard O, Minerva N, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther 2010; 31:1346-1353.
28. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1:17-24.
29. Moss AM, Endres CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice. Mol Pharm 2012; 9:2442-2449.
30. Endres CJ, Moss AM, Ke B, et al. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther 2009; 329:387-398.
31. de Kanter CT, Burger DM, Buti M, et al. Defining the therapeutic range of ribavirin with telaprevir-based triple therapy for HCV infection: is it possible? 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 19-21 May 2014, Washington, DC, USA. Abstract O-04.